Thelansis

Erosive Esophagitis (EE) Market Outlook Thelansis’s “Erosive Esophagitis (EE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Erosive Esophagitis (EE) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s tra...

Erosive Esophagitis (EE) Market Outlook Thelansis’s “Erosive Esophagitis (EE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Erosive Esophagitis (EE) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Erosive Esophagitis (EE) Overview Erosive esophagitis (EE) is a common symptom of gastroesophageal reflux disease (GERD) (GERD). Without continued treatment, most patients with healed EE (approximately 80% – 90%) will relapse within 6 – 12 months. The major esophageal complications of EE include ulcer bleeding and strictures. Although death from EE is uncommon, these complications are associated with significant morbidity and morta...

  Erosive esophagitis (EE) is a common gastroesophageal reflux disease (GERD) symptom. Without continued treatment, most patients with healed EE (approximately 80% – 90%) will relapse within 6 – 12 months. The major esophageal complications of EE include ulcer bleeding and strictures. Although death from EE is uncommon, these complications are associated with significant morbidity and mortality rates. Although there is some overlap in acid exposure among esophagitis grades, the severity of EE is related to the duration of esophageal acid exposure. Because of their ability to control esophageal acid exposure, symptoms,   and esophagitis, acid-suppressive therapy with proton pump inhibitors   (PPIs) is recommended as first-line therapy for GERD and EE. Esomeprazole is the S-enantiomer of the racemic PPI omeprazole, with which it shares the exact pharmacodynamic mechanism of action. Both of these PPIs block the proton pump H+/K+ adenosine triphosphatase.   Thelans...